Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ricklefs et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“One of themost prominent molecules used by tumor cells to engage T cell immune checkpoints is programmed death ligand 1 (PD-L1) (9, 10).”
BackgroundSelf-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Cited by
Items 301–400 of 632
Zhang, Z., Shen, X., Tan, Z., Mei, Y., Lu, T., Ji, Y., Cheng, S., Xu, Y., Wang, Z., Liu, X., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1053263 · Cited by 23
“The binding of PD-1 to PD-L1 facilitates cancer immune evasion via inhibiting T-cell function (Ricklefs et al., 2018).”
BackgroundMonteiro-Reis, S., Carvalho-Maia, C., Bart, G., Vainio, S. J., Pedro, J., Silva, E. R., Sales, G., Henrique, R., & Jerónimo, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063267 · Cited by 21
Immunomodulatory effects of extracellular vesicles in glioblastoma
Low, J. J. W., Sulaiman, S. A., Johdi, N. A., & Abu, N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.996805 · Cited by 21
“The mechanism of action is in contrast to findings by Ricklefs et al. who argue GB-derived EVs block TCR-mediated T cell activation (Ricklefs et al., 2018), although Hines et al. do point out the possible discrepancy with T cell stimulation employed by both researchers causing contrasting results…”
ResultWu, P., Guo, Y., Xiao, L., Yuan, J., Tang, C., Dong, J., & Qian, Z. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03395-6 · Cited by 23
Epstein-Barr virus LMP1 enhances levels of large extracellular vesicle-associated PD-L1
Harb, M. A., Sun, L., & Meckes, D. G. (2023) · Journal of Virology · doi:10.1128/jvi.00219-23 · Cited by 22
Schweiger, M. W., Amoozgar, Z., Repiton, P., Morris, R. T., Maksoud, S., Hla, M., Zaniewski, E. F., Noske, D. P., Haas, W., Breyne, K., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108807 · Cited by 25
“14,46 WeidentifiedapotentialpropensityofhighCD206-expressingmacrophagestotakeupEVs,suggestingtheenrichment of high mannose glycans on the EV surface, making them an ideal tool for delivery of therapeutics into CD206-expressing TAMs.”
BackgroundChimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward
Gatto, L., Nunno, V. D., Franceschi, E., & Brandes, A. A. (2021) · Immunotherapy · doi:10.2217/imt-2021-0054 · Cited by 22
Clinical implications of extracellular vesicles in neurodegenerative diseases
Vinaiphat, A., & Sze, S. K. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1657407 · Cited by 20
“[7,8] and natural killer cells [9,10] to suppress immune”
BackgroundYe, Z., Chen, W., Li, G., Huang, J., & Lei, J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10147-6 · Cited by 22
Nanotechnology Meets Stem Cell Therapy for Treating Glioblastomas: A Review
Ghosh, A. K., Ghosh, A., & Das, P. K. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04714 · Cited by 22
Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence
Graner, M. W. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015324 · Cited by 21
Yamaguchi, I., Nakajima, K., Shono, K., Mizobuchi, Y., Fujihara, T., Shikata, E., Yamaguchi, T., Kitazato, K. T., Sampetrean, O., Saya, H., et al. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz058 · Cited by 22
Re, M. D., van Schaik, R. H. N., Fogli, S., Mathijssen, R. H. J., Cucchiara, F., Capuano, A., Scavone, C., Jenster, G. W., & Danesi, R. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188463 · Cited by 20
Small Extracellular Vesicles and Metastasis—Blame the Messenger
Seibold, T., Waldenmaier, M., Seufferlein, T. T. W., & Eiseler, T. (2021) · Cancers · doi:10.3390/cancers13174380 · Cited by 22
“Inhibition of apoptosis by targeting Bax and caspase-3 [155] lncRNA-Pouf3 Glioma Pro-angiogenic gene expression in ECs [155] Lymphangiogenesis miR-221-3p CeC Expansion of lymphatic vessels via downregulationof VASH [156] LNMAT2 Bladder cancer Growth of lymphatic vessels via upregulation of PROX1 [157] Organotropism mi…”
BackgroundInfluentialImmunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy
Fekrirad, Z., Behrooz, A. B., Ghaemi, S., Khosrojerdi, A., Zarepour, A., Zarrabi, A., Arefian, E., & Ghavami, S. (2022) · Cancers · doi:10.3390/cancers14153698 · Cited by 22
“, GBM secretes extravesicles that contain PDL-1, which prevents T lymphocytes from proliferating and becoming activated [43].”
BackgroundMetabolic features of tumor-derived extracellular vesicles: challenges and opportunities
Espiau-Romera, P., Gordo-Ortiz, A., Ortiz-de-Solórzano, I., & Sancho, P. (2024) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2024.12 · Cited by 23
Proteomic Analysis of Extracellular Vesicles Derived from MDA-MB-231 Cells in Microgravity
Chen, Y., Xue, F., Russo, A., & Wan, Y. (2021) · The Protein Journal · doi:10.1007/s10930-020-09949-2 · Cited by 21
Zhand, S., Zhu, Y., Nazari, H., Sadraeian, M., Warkiani, M. E., & Jin, D. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04046 · Cited by 19
Self‐Immolated Nanoadjuvant for In Situ Vaccination Immunotherapy of Colorectal Cancer
Wang, W., Zhu, Q., Jin, Y., Gao, J., Li, J., Zheng, X., Gao, W., Saeed, M., Sheng, W., & Yu, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300524 · Cited by 21
Yang, X., Wang, W., & Ji, T. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06553-5 · Cited by 22
“%) was purchased from BioChemPartner (Shanghai, China) ; primary and secondary antibodies were from Cell Signaling (Boston, USA), IFN-γ (300-02-100) was from PeproTech (Rocky Hill, USA); and anti-human CD274 (PD-L1, 557924) was from Becton, Dickinson and Company (BD, State of New Jersey, USA).”
Balakrishnan, A., Winiarek, G., Hołówka, O., Godlewski, J. A., & Bronisz, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1540431 · Cited by 20
Self-citationmTOR Modulates Intercellular Signals for Enlargement and Infiltration in Glioblastoma Multiforme
Ryskalin, L., Biagioni, F., Lenzi, P., Frati, A., & Fornai, F. (2020) · Cancers · doi:10.3390/cancers12092486 · Cited by 19
“In addition, GBM can also evade T cell-mediated killing by shedding EVs decorated with PD-L1, thus, blocking T cell activation [142].”
BackgroundIn vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Lu, C., Chung, W.-M., Tsai, C., Cheng, J., Hsu, K., & Tzeng, H.-E. (2022) · Scientific Reports · doi:10.1038/s41598-021-03590-4 · Cited by 22
Exosome-mediated transduction of mechanical force regulates prostate cancer migration via microRNA
Liu, Z., Jin, Q., Yan, T.-F., Wo, Y., Liu, H., & Wang, Y. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101299 · Cited by 24
Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
Mishra, S., Amatya, S. B., Salmi, S., Koivukangas, V., Karihtala, P., & Reunanen, J. (2022) · Cancers · doi:10.3390/cancers14205121 · Cited by 19
Horizontal Transfer of Malignant Traits and the Involvement of Extracellular Vesicles in Metastasis
Arena, G. O., Forte, S., Abdouh, M., Vanier, C. H., Corbeil, D., & Lorico, A. (2023) · Cells · doi:10.3390/cells12121566 · Cited by 19
Huang, Z., Deng, C., Ma, C., He, G., Tao, J., Zhang, L., Hu, X., Mo, Y., Qiu, L., Zhang, N., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001533 · Cited by 21
“Animal model results demonstrated that PD-L1 + EVs secreted by melanoma and glioma cells suppressed the proliferation of CD8 + T cells and reduced lymphocyte in fi ltration in tumour tissues [29,30] .”
ResultImmune checkpoint pathways in glioblastoma: a diverse and evolving landscape
Inocencio, J. F., Mitrasinovic, S., Asad, M., Parney, I. F., Zang, X., & Himes, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424396 · Cited by 23
“…vesicles (EVs) have also been implicated in maintaining the immunosuppressive milieu in GBM. EVs are bilipid layer particles of varying sizes that are released from various types of cells and contain bioactive ) (41), polarize TAMs into an immunosuppressive phenotype (42), and induce MDSCs (43).”
BackgroundExosomes as a Therapeutic Strategy in Cancer: Potential Roles as Drug Carriers and Immune Modulators
Abedi, A., Moghaddam, M. M., Kachuei, R., & Fooladi, A. A. I. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189238 · Cited by 22
Du, X., Chen, S., Meng, T., Liu, L., Li, L., Xiang, R., Zhang, H., Zhu, Y., Zhang, X., Lin, S., et al. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100031 · Cited by 20
Extracellular Vesicles Containing PD-L1 Contribute to Immune Evasion in Glioblastoma
Lubin, J. A., Zhang, R. R., & Kuo, J. S. (2018) · Neurosurgery · doi:10.1093/neuros/nyy295 · Cited by 18
Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment
Feldman, L. A., Brown, C. E., & Badie, B. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa584 · Cited by 21
Oncolytic Virus Therapy Alters the Secretome of Targeted Glioblastoma Cells
Godlewski, J. A., Farhath, M. M., Ricklefs, F. L., Passaro, C., Kiel, K., Nakashima, H., Chiocca, E. A., & Bronisz, A. (2021) · Cancers · doi:10.3390/cancers13061287 · Cited by 18
Self-citationZhu, F., Ji, Y., Li, L., Bai, X., Liu, X., Luo, Y., Liu, T., Lin, B., & Lu, Y. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01446 · Cited by 18
Shao, B., Dang, Q., Chen, Z., Chen, C., Zhou, Q., Qiao, B., Liu, J., Hu, S., Wang, G., Yuan, W., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.760211 · Cited by 18
Self-citationDrug Resistance in Glioma Cells Induced by a Mesenchymal–Amoeboid Migratory Switch
Ketchen, S., Gamboa-Esteves, F. O., Lawler, S. E., Nowicki, M. O., Rohwedder, A., Knipp, S., Prior, S., Short, S. C., Ladbury, J. E., & Brüning‐Richardson, A. (2021) · Biomedicines · doi:10.3390/biomedicines10010009 · Cited by 19
“HOG and G44 were grown as neurospheres suspended in neurobasal medium (ThermoFisher, Altrincham, UK) containing B27 supplement, 0.5% penicillin-streptomycin (Ther- Biomedicines 2022, 10, 9 3 of 16 moFisher, Altrincham, UK), glutamine (ThermoFisher, Altrincham, UK), EGF and FGF (ThermoFisher, Altrincham, UK).”
BackgroundSelf-citationVillazon, J. I., Cruz, N. D., & Shi, L. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06966 · Cited by 18
Nourizadeh, M., Mounesyar, S. M., Movahhed, M. S., Alipour, K., Zekavatbakhsh, R., Hoseinzadeh, M., Davari, S., Amirhooshangi, M., Amirhoushangi, H., & Hamzehzadeh, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03807-2 · Cited by 21
“In vitro studies show that this suppression can be partially reversed by PD-1 blockade, confirming EV PD-L1’s role [50].”
Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review
Acharya, R. K., Mahapatra, A., Verma, H. K., & Bhaskar, L. V. (2023) · Current Oncology · doi:10.3390/curroncol30110691 · Cited by 20
“118].”
BackgroundImmune Checkpoint-Blocking Nanocages Cross the Blood–Brain Barrier and Impede Brain Tumor Growth
Kim, M., Yoon, H. J., Lee, C., Lee, M., Park, R., Lee, B.-H., Park, E. J., & Kim, I.-S. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01200 · Cited by 17
Proneural-mesenchymal antagonism dominates the patterns of phenotypic heterogeneity in glioblastoma
Harshavardhan, B. V., & Jolly, M. K. (2024) · iScience · doi:10.1016/j.isci.2024.109184 · Cited by 18
“38,39 The observed association of PD-L1 with mesenchymal subgroup in GBM 40–42 also reinforces our analysis; functionally, PD-L1 can trigger more aggressive GBM behavior through the downstream Ras/Erk signaling.”
ResultHarnessing EV communication to restore antitumor immunity
Massaro, C., Min, W., Pegtel, D. M., & Baglio, S. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113838 · Cited by 17
Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy
Xu, J., Cao, W., Wang, P., & Liu, H. (2022) · Pharmaceuticals · doi:10.3390/ph15070876 · Cited by 17
The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas
Yekula, A., Taylor, A., Beecroft, A., Kang, K. M., Small, J. L., Muralidharan, K., Rosh, Z. S., Carter, B. S., & Balaj, L. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.61 · Cited by 24
“EVs are conduits for communication between cells, transporting molecular cargo including proteins, nucleic acids, and lipids from cell to cell([9,10]).”
BackgroundSelf-citationKrenzlin, H., Zdioruk, M. I., Nowicki, M. O., Finkelberg, T., Keric, N., Lemmermann, N. A. W., Skubal, M., Chiocca, E. A., Cook, C. H., & Lawler, S. E. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.005 · Cited by 16
Self-citationCan Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?
Joseph, J., Rahmani, B., Cole, Y., Puttagunta, N., Lin, E., Khan, Z. K., & Jain, P. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10018-3 · Cited by 17
Shedding light on function of long non-coding RNAs (lncRNAs) in glioblastoma
Hashemi, M., Roshanzamir, S. M., Orouei, S., Daneii, P., Raesi, R., Zokaee, H., Bikarannejad, P., Salmani, K., Khorrami, R., Paskeh, M. D. A., et al. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.02.002 · Cited by 16
“The extracellular vesicles derived from GBM cells contain PD-L1 as the ligand of PD-1 that can bind to PD-1 to inhibit T-cell activation and proliferation, leading to immune evasion [158].”
BackgroundSanchez, J. C., Pierpont, T. M., Argueta-Zamora, D., Wilson, K. F., August, A., & Cerione, R. A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108143 · Cited by 19
“38,39 40–44 Therefore, we were interested in investigating how PTEN/PI3K signaling influences the biogenesis of EVs and the presence of PD-L1 as EV-associated cargo.”
Luo, X., Kugeratski, F. G., Dowlatshahi, D. P., Sugimoto, H., Arian, K. A., Fan, Y., Huang, L., Wills, D., Lilla, S., Hodge, K., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c09688 · Cited by 19
Pancholi, S., Tripathi, A., Bhan, A., Acharya, M. M., & Pillai, P. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02752-3 · Cited by 16
“Glioblastoma stem cell–derived EVs (GSC-derived EVs) expressing PD-L1 are reported to suppress T cell activation, one of the possible immune evasion strategy adapted by GBM cells [118].”
BackgroundThe emerging roles of PD-L1 subcellular localization in tumor immune evasion
Liu, D., Wen, C., Chen, L., Ye, M., Liu, H., Sun, X., Liang, L., Zhang, J., Shi, C., & Liu, J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115984 · Cited by 17
Gui, H., Wang, W., Xue, Y., Zhao, W., Wang, M., Shi, L., & Wang, X. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216784 · Cited by 15
Shi, X., Zhao, X., He, Y., Zhang, L., Zheng, X., Qin, X., Li, K., Li, J., Wang, Y., Dai, L., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113961 · Cited by 17
Guo, M., Yuan, Z., Jin, X. J., Li, X., Deng, Y., Zhou, S., Niu, R., Bae, J., Park, J. B., Shi, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63796-2 · Cited by 25
“Notably, the intratumoral heterogeneity inherent in GSCs presents various mechanisms that attenuate the response to ICB therapy and diminish its anti-tumor effectiveness 9,10 .”
Carreau, N. A., & Diefenbach, C. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719846451 · Cited by 15
Lipinski, S., & Tiemann, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073374 · Cited by 16
Petterson, S. A., Sørensen, M. D., Burton, M., Thomassen, M., Kruse, T. A., Michaelsen, S. R., & Kristensen, B. W. (2022) · Brain Pathology · doi:10.1111/bpa.13111 · Cited by 18
“Another previous study suggested that PD-L1 was enriched in perinecrotic and pseudopalisading niches of GBMs, but this finding was obtained using IvyGAP mRNA data [56] and did not report on the protein level.”
ResultLi, X., Duan, Z., Li, Z., Gu, L., Li, Y., Gong, Q., Gu, Z., & Luo, K. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122294 · Cited by 16
ExoPD-L1: an assistant for tumor progression and potential diagnostic marker
Hu, R. H., Jahan, M. S., & Tang, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1194180 · Cited by 14
Petrovic, M., Majchrzak, O. B., Marecar, R. A. M. H., Laingoniaina, A. C., Walker, P. R., Borchard, G., Jordan, O., & Tankov, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312787 · Cited by 15
“In GBM, for example, EVs were shown to carry PD-L1, which can engage PD-1 receptors on macrophages, suppressing macrophage pro-inflammatory activity and fostering a tolerogenic, immunosuppressive phenotype that supports tumor growth [8,9].”
Wang, X., Yang, X., Huang, C., Liu, T., Zang, H., Gu, Y., Zhang, Y., Zhu, X., Zhang, C., Guo, F., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217486 · Cited by 15
Biolato, A. M., Filali, L., Wurzer, H., Hoffmann, C., Gargiulo, E., Valitutti, S., & Thomas, C. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.07.001 · Cited by 17
van Solinge, T. S., Abels, E. R., van de Haar, L. L., Hanlon, K. S., Maas, S. L. N., Schnoor, R., de Vrij, J., Breakefield, X. O., & Broekman, M. L. D. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.554649 · Cited by 15
Self-citationSpatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma
Müller, S., Mayer, S. C., Möller, P., Barth, T. F. E., & Marienfeld, R. B. (2021) · Neoplasia · doi:10.1016/j.neo.2021.05.005 · Cited by 15
Emerging Role of Extracellular Vesicles in Prostate Cancer
Ludwig, M., Rajvansh, R., & Drake, J. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab139 · Cited by 15
“PD-L1 has also been found on the surface of EVs in several cancer types (90-92) and shown to be capable of binding PD-1 on T-cells (93).”
BackgroundSourani, A., Saghaei, S., Saboori, M., Soleimani, M., & Dehghani, L. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06687-1 · Cited by 15
“Other citations used protein [36, 47, 51, 52, 54], enzyme [43], or other metabolites [20, 22, 24, 33, 55, 56] as EV cargos for discriminating between glioma patients and healthy controls or high-grade and low-grade gliomas with diagnostic values ranging from 80% to more than 90%.”
BackgroundThe interweaving relationship between extracellular vesicles and T cells in cancer
Abu, N., & Bakarurraini, N. A. A. R. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.007 · Cited by 14
Extracellular vesicle-based checkpoint regulation and immune state in cancer
Mortezaee, K., & Majidpoor, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01837-2 · Cited by 16
“Compared to the proneural subset, mesenchymal subtype shows considerable expression of PD-L1, which is indicative of different responses among GBM subtypes to ICI therapy [42].”
BackgroundLeukobiopsy – A Possible New Liquid Biopsy Platform for Detecting Oncogenic Mutations
Chennakrishnaiah, S., Tsering, T., Aprikian, S., & Rak, J. W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01608 · Cited by 14
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
Feldman, L. A., Brown, C. E., & Badie, B. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08689-5 · Cited by 17
Martínez, L. E., Lensing, S., Chang, D., Magpantay, L. I., Mitsuyasu, R. T., Ambinder, R. F., Sparano, J. A., Martínez-Maza, O., & Epeldegui, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-13101-8 · Cited by 13
Liu, C., Lin, H., Yu, H., Mai, X., Pan, W., Guo, J., Liao, T., Feng, J., Zhang, Y., Situ, B., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303430 · Cited by 13
The role of extracellular vesicle immune checkpoints in cancer
Zhang, W., Ou, M., Yang, P., & Ning, M. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae026 · Cited by 13
Ghazi, B., Harmak, Z., Rghioui, M., Kone, A.-S., Ghanmi, A. E., & Badou, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1423232 · Cited by 15
“…TGF-b , IL-10, and heat shock proteins) as well as PD-L1, which binds to the PD-1 receptor on the surface of tumor-in fi ltrating lymphocytes (TILs) and leads to cancer immune evasion through the inhibition of T-cell responses and, in turn, decreased survival outcomes in cancer patients (106 – 108).”
BackgroundInfluentialRajendran, A. T., Rajesh, G. D., Ashtekar, H., Sairam, A., Kumar, P., & Vadakkepushpakath, A. N. (2024) · Scientific Reports · doi:10.1038/s41598-024-72475-z · Cited by 13
“This approach has demonstrated remarkable efficacy in treating some tumor types 7 .”
BackgroundUpdate on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 16
Krapež, G., Kouter, K., Jovčevska, I., & Paska, A. V. (2022) · Biomedicines · doi:10.3390/biomedicines10010151 · Cited by 13
“One of the mechanisms is by binding of PD-L1, which is found on tumor and antigen presenting cells, to programmed cell death protein 1 (PD1) which is found on activated T-cells, therefore blocking T-cell activation and inhibiting Tcell killing of tumor cells [68].”
BackgroundTumor-Derived Exosomes Regulate Apoptosis of CD45+EpCAM+ Cells in Lung Cancer
Lu, S., Sun, Z., Liu, L., Li, P., Li, B., Li, W., Wu, Z., Zhao, M., Liu, W., Wang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903882 · Cited by 15
“Acting as cellular substitutions, exosomes are important contributors to the damnification of the immune system (22).”
BackgroundWestphal, M., Pantel, K., Ricklefs, F. L., Maire, C. L., Riethdorf, S., Mohme, M., Wikman, H., & Lamszus, K. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac015 · Cited by 13
Self-citationImmunological and clinicopathological characteristics of C1RL in 2120 glioma patients
Wang, J., Tong, L., Lin, G., Wang, H., Zhang, L., & Yang, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-07436-6 · Cited by 13
Tumor‐associated macrophages as treatment targets in glioma
Peng, Y., Chen, F., Li, S., Liu, X., Wang, C., Yu, C., & Li, W. (2020) · Brain Science Advances · doi:10.26599/bsa.2020.9050015 · Cited by 13
“One possible mechanism for the immune escape in GBM is through the interaction between PD‐1 and extracellular vesicles secreted by GBM cells [101].”
BackgroundHuang, K., Hu, M., Chen, J., Wei, J., Qin, J., Lin, S., & Du, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105158 · Cited by 14
“However, several studies have reported that tumor cells are able to release a vast of exosomes, containing majority PD-L1, to suppress antitumor immunity rather than merely present PD-L1 on their cell surfaces [22,23].”
BackgroundRe, M. D., Vivaldi, C., Rofi, E., Salani, F., Crucitta, S., Catanese, S., Fontanelli, L., Massa, V., Cucchiara, F., Fornaro, L., et al. (2021) · Cancers · doi:10.3390/cancers13153738 · Cited by 13
“However, it is founded on the evidence that PD-L1 expression is detected in pancreatic carcinoma [48] and the PD-L1 protein is commonly found on the surface of tumor-derived MVs [49] including PDAC [50].”
BackgroundInfluentialNikoobakht, M., Shamshiripour, P., Shahin, M., Bouzari, B., Hashemi, M. R., Ahmadvand, D., & Akbarpour, M. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100490 · Cited by 13
Comprehensive analysis of inhibitory checkpoint ligand expression by glioblastoma cells
Robilliard, L. D., Yu, J. J., Anchan, A., Joseph, W. R., Finlay, G. J., Angel, C. E., & Graham, E. S. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12428 · Cited by 13
Tumor-derived extracellular vesicles: how they mediate glioma immunosuppression
Ma, T., Su, G., Wu, Q., Shen, M., Feng, X., & Zhang, Z. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09196-5 · Cited by 12
“It could bind directly to PD1, leading to immune evasion in the tumor by suppressing T cell function [72].”
Liu, J., Qin, J., Liang, L., Zhang, X., Gao, J., Hao, Y., & Zhao, P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176831 · Cited by 12
Tumor-derived extracellular vesicles: Hijacking T cell function through exhaustion
Guo, R., & Wang, P. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155948 · Cited by 12
Assunção, R. R. S., Santos, N. L., & Andrade, L. N. D. S. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100635 · Cited by 12
“40 Zhu et al. 41 also described PD-L1 + EVs as a potential biomarker in cancer disease, not only for diagnosis, but also for prediction of immunotherapy outcome.”
Kiełbowski, K., Plewa, P., Szulc, J., Ćmil, M., Bakinowska, E., & Pawlik, A. (2025) · Biomedicines · doi:10.3390/biomedicines13061356 · Cited by 14
Dibavar, M. A., Pourbagheri‐Sigaroodi, A., Asemani, Y., Salari, S., & Bashash, D. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119177 · Cited by 12
Gatto, L., Franceschi, E., Nunno, V. D., Maggio, I., Lodi, R., & Brandes, A. A. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1997599 · Cited by 12
Cancer as an infective disease: the role of EVs in tumorigenesis
de Lope, L. R., Sánchez‐Herrero, E., Serna‐Blasco, R., Provencio, M., & Romero, A. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13316 · Cited by 13
Roles of extracellular vesicles in glioblastoma: foes, friends and informers
Lunavat, T. R., Nieland, L., Vrijmoet, A. B., Zargani‐Piccardi, A., Samaha, Y., Breyne, K., & Breakefield, X. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1291177 · Cited by 12
“…able by the CD169 marker contributes to the establishment of an anti-tumor surrounding within GB. molecules, such as checkpoint inhibitor proteins - programmed death ligand-1 (PD-L1;(28), cytotoxic T-lymphocyte associated protein 4 (CTLA-4;(50), and immunosuppressive cytokines, such as TGF-b (29).”
BackgroundSelf-citationAnti-Cancer Role and Therapeutic Potential of Extracellular Vesicles
Tominaga, N. (2021) · Cancers · doi:10.3390/cancers13246303 · Cited by 13
Kiya, Y., Yoshioka, Y., Nagakawa, Y., & Ochiya, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021362 · Cited by 13
“When IFN-γ upregulates PD-L1 expression on the surface of tumor cells, PD-L1 is also expressed on the surface of tumor-derived EVs and suppresses T-cell activation and proliferation [70,71]; furthermore, there is a correlation between PD-L1 expression levels in tumor tissues and those in EVs [72,73].”
BackgroundChoi, D., Kang, T. G., Kim, T., Moon, C.-W., Choi, M., Kim, D., Kim, T., Oh, Y., Sung-Won, J., Lee, Y., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102237 · Cited by 11
A TRP to Pathological Angiogenesis and Vascular Normalization
Katari, V., Dalal, K. K., Adapala, R. K., Guarino, B. D., Kondapalli, N. B., Paruchuri, S. M., & Thodeti, C. K. (2024) · Comprehensive physiology · doi:10.1002/cphy.c230014 · Cited by 12
Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress
Manoochehri, H., La’ah, A. S., Babaeizad, A., Sheykhhasan, M., Rostamipoor, M., Abbaspoor, M., Nikravesh, F., Khosravi, S. M., Mahaki, H., Tanzadehpanah, H., et al. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101065 · Cited by 24
Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor
Kiel, K., Piranlioglu, R., Godlewski, J. A., & Bronisz, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1588081 · Cited by 12
Self-citation
Metadata
- Authors
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Berkeley (US)
- Massachusetts General Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of California San Diego (US)
- Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
- Harvard University (US)
- Corresponding author
- Lawler, Sean E.
- Chiocca, E. Antonio
- ORCID
- Ricklefs, Franz L.
- Alayo, Quazim
- Krenzlin, Harald
- Mahmoud, Ahmad B.
- Speranza, Maria C.
- Nakashima, Hiroshi
- Hayes, Josie L.
- Lee, Kyungheon
- Balaj, Leonora
- Passaro, Carmela
- Rooj, Arun K.
- Krasemann, Susanne
- Carter, Bob S.
- Chen, Clark C.
- Steed, Tyler
- Treiber, Jeffrey
- Rodig, Scott
- Yang, Katherine
- Nakano, Ichiro
- Lee, Hakho
- Weissleder, Ralph
- Breakefield, Xandra O.
- Godlewski, Jakub
- Westphal, Manfred
- Lamszus, Katrin
- Freeman, Gordon J.
- Bronisz, Agnieszka
- Lawler, Sean E.
- Chiocca, E. Antonio
- Venue
- Science Advances
- Published
- 2018-03-02
- Volume
- 4
- Issue
- 3
- Pages
- eaar2766-eaar2766
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC5842038
- OpenAlex
- W2793992337
- Cited by
- 610
- References
- 42
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Science Advances (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (CA176203-01A1)
- National Cancer Institute (P01 CA69246)
- Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
- National Institute of Health (NCI P01 CA69246)
- American-Italian Cancer Foundation Post-doctoral Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
- MeSH terms
- Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.